fda bpc-157 unapproved drug warning East Texas expert warns of new peptide drugs trending on social media: 'There might be some beneficial effects that we can utilize, but there are also some potential unknowns,' Dr. Alex Jacobsen BPC-157 Before the FDA: Briefing

What is the difference between Choquequirao and the Inca ruins of Machu Picchu

In STEP 1, participants without diabetes who received semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks compared to 2.4% with placebo

BPC-157 is a promising option for individuals dealing with soft tissue injuries

Variability in carbon fluxes, uncertainties in sequestration permanence, and methodological inconsistencies across life-cycle assessments hinder reliable quantification of net reductions

Pinpointing the cause is a huge step forward, and thankfully, the path to feeling better is often straightforward and very effective